Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine (Vraylar): Evaluating Its Antidepressant Benefit

NCT05060549 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT05060549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05060549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine (Vraylar): Evaluating Its Antidepressant Benefit
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 4
Overall status
Withdrawn
Start date
January 6, 2026
Completion date
May 1, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression